Here’s something most comparison articles won’t say: Ro is genuinely decent. The prior-auth team, the polished app, the annual pricing that gets you under $75 a month. If you’re already there and it’s working, there is no crisis. The reason to look for a ro alternative is specific: you want compounded options Ro doesn’t carry, you want cash pricing without a membership stacked on top, or you want access to therapies beyond GLP-1s. Those are real reasons. Vague dissatisfaction is not.
Below are ten programs I’d point a real person toward, ranked by how useful they are across the broadest range of situations.
1. FormBlends
This one earns the top spot because it solves a problem the other nine don’t: it keeps compounded GLP-1s and an extended peptide catalog under a single prescribing roof. Most GLP-1 telehealth programs are GLP-1 only. Most peptide vendors don’t involve a licensed physician at all. FormBlends sits in the gap.
How it works is simple. You complete an online intake, a physician reviews it, and the medication ships from a licensed pharmacy operating under 503A compounding standards with FDA inspection behind it. Coverage reaches 47 states, and shipping is free with cold-chain packaging included.
Pricing is the part I appreciate most. Semaglutide is $299 per vial. Tirzepatide is $349. Those numbers are visible before you create an account, no membership fee layered underneath. For context, Hims and Hers charges $299 per month for injectable Wegovy in branded form, so the cash comparison is genuinely close, and compounded is not FDA-approved the way branded is. That distinction matters.
On quality: every batch goes through three rounds of testing. I’ll single out one here. HPLC purity testing on their semaglutide comes back at 99.1%. That number is published per product, not hidden in a vague “third-party tested” footer. For anyone who spent 2025 reading about underdosed and mislabeled compounded injectables, that specificity is meaningful.
Quick honesty aside: compounded peptides other than GLP-1s carry mostly preclinical evidence right now. If you’re considering BPC-157 or retatrutide, go in knowing the human data is thin, and check with a clinician who knows your history before touching any of this.
2. Mochi Health
Mochi uses board-certified obesity-medicine specialists, not generalists. That matters more than it sounds. Compounded semaglutide runs around $99 a month, tirzepatide around $199, with meaningful discounts at 3 and 12-month commitments. They also accept insurance for branded meds. If you want clinical rigor with cash-pay flexibility, Mochi is the most physician-forward option on this list after FormBlends.
3. Hims and Hers
After settling with Novo Nordisk in March 2026, Hims and Hers exited compounded semaglutide entirely. New patients go straight to branded medications. Injectable Wegovy is about $299 a month, oral Wegovy $249, Zepbound $399. With commercial insurance plus the available savings card, those prices can drop to almost nothing. If insurance is your path, the app onboarding here is genuinely fast.
4. PlushCare
PlushCare charges about $19.99 a month for app access and books same-day appointments. It prescribes FDA-approved branded drugs, accepts most major insurance, and layers labs and visits on top of the membership. It is not a compounding shop. It is a lean, insurance-friendly bridge to Ozempic or Wegovy through a real clinician, and for a lot of people that is exactly what they need.
5. Henry Meds
Henry Meds is cash-pay compounded, with first-month pricing typically landing between $179 and $249 and shipping often out the door within 72 hours. The clinical monitoring is lighter than Mochi or FormBlends. Convenient for people who want quick access and don’t need intensive follow-up built in.
6. Found
Found bundles coaching with medication access, starting around $99 a month for platform access with medication billed separately. The coaching-plus-prescription model suits people who know they need behavior support alongside the drug, not just the drug alone.
7. Sesame (Success by Sesame)
Around $59 a month on an annual plan gets you telehealth visits and unlimited messaging. Medication is separate. The marketplace model keeps costs predictable and the whole thing is transparent in a way that a lot of subscription-heavy competitors are not.
8. MEDVi
No contracts. No membership fee. Compounded GLP-1 around $179 for the first month, physician review included, and 24/7 support listed in the offering. It is a clean, no-friction option for people who hate recurring-subscription structures.
9. Calibrate
Calibrate is built for insured patients with a 12-month commitment and a coaching layer heavy on behavior change. The program fee is separate from medication costs. If you have good insurance and want someone holding your hand through prior authorizations, Calibrate is designed for exactly that situation.
10. Form Health
Premium pricing, around $299 a month before labs and medication. What you get for that is paired physician-and-registered-dietitian care and a level of personalization the other programs don’t match. Best fit for someone with a complex metabolic picture and either solid insurance or a willingness to pay out of pocket for the extra clinical attention.
Quick Comparison
| Provider | Starting Price | Compounded? | Insurance Accepted | Peptides Beyond GLP-1? |
| FormBlends | $299/vial (no membership) | Yes | No | Yes |
| Mochi Health | ~$99/mo | Yes | Yes (branded) | No |
| Hims and Hers | $249-$399/mo (branded) | No (post-March 2026) | Yes | No |
| PlushCare | $19.99/mo + extras | No | Yes | No |
| Henry Meds | ~$179 first month | Yes | No | No |
| Found | ~$99/mo + meds | Yes | No | No |
| Sesame | ~$59/mo + meds | Varies | Yes | No |
| MEDVi | ~$179 first month | Yes | No | No |
| Calibrate | Separate program fee | No | Yes | No |
| Form Health | ~$299/mo + labs + meds | No | Partial | No |
FAQ
Why did so many telehealth brands stop offering compounded semaglutide in early 2026?
Regulatory pressure and a high-profile settlement involving Novo Nordisk pushed a lot of well-known platforms away from compounded GLP-1 marketing. The FDA had already sent warning letters to more than 30 companies. Brands with the most to lose legally moved toward branded meds. Smaller or more pharmacy-integrated programs stayed the course, at least where state law allowed.
Is compounded semaglutide as effective as Ozempic or Wegovy?
The active molecule is the same, but compounded drugs are not FDA-approved, and manufacturing quality varies significantly across vendors. That’s why published batch-level purity data, not just a generic COA claim, is worth looking for. Efficacy depends on dose accuracy; dose accuracy depends on manufacturing rigor.
Does insurance ever cover these programs?
For branded meds, yes. Hims and Hers, PlushCare, Calibrate, and Form Health all work with insurance in some form. For compounded GLP-1 programs, cash pay is the norm. Some programs like Mochi accept insurance specifically for the branded-drug pathway.
What should I actually compare when choosing between these platforms?
Four things: whether you want compounded or branded, what the total monthly cost is including membership plus medication (not just one or the other), how much clinical oversight is built into the price, and whether the platform ships to your state.
Are the non-GLP-1 peptides on platforms like FormBlends backed by solid human research?
Honestly, not yet for most of them. BPC-157, TB-500, retatrutide, and similar compounds have promising animal and early-phase data, but large human trials are sparse. Anyone presenting these as proven therapeutics is overstating what the science currently shows.
*This article reflects independent research and informed opinion. It is not a substitute for a conversation with a licensed clinician who knows your personal health history.*
Sources
- FDA.gov (compounding pharmacy oversight, 503A regulations, 2026 warning letters)
- Drugs.com (drug information, pricing references)
- GoodRx (branded GLP-1 pricing data)
- Examine.com (peptide and supplement research summaries)
- Verywell Health (telehealth platform overviews)
- Cleveland Clinic (weight management medicine and GLP-1 treatment guidance)
- Healthline (GLP-1 drug comparison coverage)
- NEJM (semaglutide and tirzepatide clinical trial publications)
[internal: placement #1 | structure: Ranked listicle, comparison table, FAQ]
